Clinical Trials

• A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
  September 23, 2022
  Conditions:   Alzheimers Disease;   Dementia;   Alzheimers Disease, FamilialInterventions:   Drug: Gantenerumab;   Drug: Matching Placebo (Gantenerumab)Sponsors:   Washington University School of Medicine;   Hoffmann-La Roche;   Alzheimer's Association;   National Institute on Aging (NIA);   Genentech, Inc.Suspended
• Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease
  May 4, 2022
  Condition:   Alzheimer DiseaseInterventions:   Drug: 18F-Flortaucipir radiopharmaceutical;   Drug: 18F-MK-6240 radiopharmaceutical;   Drug: Amyloid-β radiopharmaceutical (11C-PiB or 18F-Florbetaben or 18F-NAV-4694)Sponsors:   Tharick Pascoal;   National Institute on Aging (NIA)Recruiting
• Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
  March 8, 2022
  Conditions:   Alzheimers Disease;   Dementia;   Alzheimers Disease, FamilialInterventions:   Drug: E2814;   Drug: Lecanemab;   Drug: Matching Placebo (E2814)Sponsors:   Washington University School of Medicine;   Alzheimer's Association;   National Institute on Aging (NIA);   Accelerating Medicines Partnership (AMP);   Eisai Inc.Recruiting
• Imaging Biomarkers in Obesity
  October 14, 2021
  Conditions:   Alzheimer Disease;   Obesity;   Metabolic DiseaseIntervention:   Sponsor:   Cyrus A RajiRecruiting
• Returning Research Results That Indicate Risk of Alzheimer Disease Dementia to Healthy Participants in Longitudinal Studies
  January 7, 2021
  Conditions:   Alzheimer Disease;   Dementia of Alzheimer TypeIntervention:   Other: Arm A , Arm B, Arm C, & Arm DSponsor:   Washington University School of MedicineEnrolling by invitation
• Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
  November 10, 2020
  Conditions:   Alzheimers Disease;   Dementia;   Alzheimers Disease, FamilialInterventions:   Drug: Gantenerumab;   Drug: Solanezumab;   Drug: Matching Placebo (Gantenerumab);   Drug: Matching Placebo (Solanezumab)Sponsors:   Washington University School of Medicine;   Eli Lilly and Company;   Hoffmann-La Roche;   Alzheimer's Association;   National Institute on Aging (NIA);   Avid Radiopharmaceuticals;   Accelerating Medicines Partnership (AMP)Completed
• A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease
  August 20, 2020
  Condition:   Alzheimer DiseaseInterventions:   Drug: GV-971;   Drug: PlaceboSponsor:   Green Valley (Shanghai) Pharmaceuticals Co., Ltd.Suspended
• Neurofilament Surveillance Project (NSP)
  August 18, 2020
  Conditions:   Frontotemporal Dementia;   Frontotemporal Lobar Degeneration;   FTD-GRNIntervention:   Sponsors:   The Bluefield Project to Cure Frontotemporal Dementia;   Mayo Clinic;   University of California, San FranciscoRecruiting
• Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
  February 10, 2020
  Conditions:   Cognitive Impairment, Mild;   Dementia;   Cardiovascular DiseasesInterventions:   Drug: Atorvastatin 40 Mg Oral Tablet;   Drug: Placebo oral tabletSponsors:   Duke University;   National Institute on Aging (NIA);   National Heart, Lung, and Blood Institute (NHLBI);   Wake Forest University Health SciencesRecruiting
• Investigations of Dementia in Parkinson Disease
  May 5, 2016
  Condition:   ParkinsonsIntervention:   Radiation: PiB and VATSponsors:   Washington University School of Medicine;   National Institutes of Health (NIH);   National Institute of Neurological Disorders and Stroke (NINDS);   National Institute on Aging (NIA)Recruiting
• Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
  January 3, 2013
  Conditions:   Alzheimers Disease;   Dementia;   Alzheimers Disease, FamilialInterventions:   Drug: Gantenerumab;   Drug: Solanezumab;   Drug: Matching Placebo (Gantenerumab);   Drug: Matching Placebo (Solanezumab);   Drug: E2814;   Drug: Lecanemab;   Drug: Matching Placebo (E2814)Sponsors:   Washington University School of Medicine;   Eli Lilly and Company;   Hoffmann-La Roche;   Alzheimer's Association;   National Institute on Aging (NIA);   Avid Radiopharmaceuticals;   Accelerating Medicines Partnership (AMP);   Eisai Inc.;   Janssen, LPRecruiting
• Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
  April 10, 2012
  Condition:   Huntington's DiseaseIntervention:   Sponsor:   CHDI Foundation, Inc.Recruiting
• Dominantly Inherited Alzheimer Network (DIAN)
  March 26, 2009
  Condition:   Alzheimer's DiseaseIntervention:   Sponsors:   Washington University School of Medicine;   National Institute on Aging (NIA)Recruiting

For a more comprehensive list of our Alzheimer disease clinical trials, please visit the Knight ADRC website, the Knight ADRC Clinical Trials Unit website and DIAN website.

• Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex
  July 29, 2016
  Condition:   Tuberous Sclerosis ComplexInterventions:   Drug: Vigabatrin;   Drug: PlaceboSponsors:   Martina Bebin;   National Institute of Neurological Disorders and Stroke (NINDS)Completed

• Longitudinal Characterization of Respiratory Tract Exacerbations and Treatment Responses in Primary Ciliary Dyskinesia
  December 17, 2021
  Conditions:   Primary Ciliary Dyskinesia;   Kartagener SyndromeIntervention:   Sponsors:   University of North Carolina, Chapel Hill;   Washington University School of Medicine;   Children's Hospital Colorado;   Stanford University;   Seattle Children's Hospital;   The Hospital for Sick Children;   McGill University;   Children's Hospital Medical Center, CincinnatiRecruiting
• Characterizing the Upper Airway Manifestations in Primary Ciliary Dyskinesia and Primary Immunodeficiencies
  June 9, 2021
  Conditions:   Primary Ciliary Dyskinesia;   Kartagener Syndrome;   Primary Immune DeficiencyIntervention:   Sponsors:   University of North Carolina, Chapel Hill;   Washington University School of Medicine;   The Hospital for Sick Children;   McGill University;   Children's Hospital Medical Center, Cincinnati;   National Heart, Lung, and Blood Institute (NHLBI)Recruiting
• Defining the Genetic Etiology of Suppurative Lung Disease in Children and Adults
  January 8, 2021
  Conditions:   Primary Ciliary Dyskinesia;   Primary Immune Deficiency;   Kartagener SyndromeInterventions:   Diagnostic Test: Genetic Testing for PCD or PID;   Other: Unaffected Family Member Genetic TestingSponsors:   University of North Carolina, Chapel Hill;   Washington University School of Medicine;   National Heart, Lung, and Blood Institute (NHLBI);   Children's Hospital Colorado;   Stanford University;   Seattle Children's Hospital;   The Hospital for Sick Children;   McGill University;   Children's Hospital Medical Center, CincinnatiRecruiting
• Light Therapy for PD – Dose Selection
  March 2, 2020
  Conditions:   Parkinson Disease;   Sleep Disorder;   FatigueIntervention:   Device: SunRay Light BoxesSponsor:   Massachusetts General HospitalActive, not recruiting
• Physical Therapy and Deep Brain Stimulation in Parkinson Disease
  June 8, 2017
  Condition:   Parkinson DiseaseIntervention:   Behavioral: Physical TherapySponsors:   Washington University School of Medicine;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Completed
• Investigations of Dementia in Parkinson Disease
  May 5, 2016
  Condition:   ParkinsonsIntervention:   Radiation: PiB and VATSponsors:   Washington University School of Medicine;   National Institutes of Health (NIH);   National Institute of Neurological Disorders and Stroke (NINDS);   National Institute on Aging (NIA)Recruiting
• Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
  April 10, 2012
  Condition:   Huntington's DiseaseIntervention:   Sponsor:   CHDI Foundation, Inc.Recruiting

• Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis
  August 3, 2020
  Condition:   Multiple SclerosisIntervention:   Diagnostic Test: MRISponsors:   The Cleveland Clinic;   National Institutes of Health (NIH);   National Institute of Neurological Disorders and Stroke (NINDS);   University of Pennsylvania;   Cedars-Sinai Medical CenterActive, not recruiting
• Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
  September 14, 2017
  Conditions:   Primary Progressive Multiple Sclerosis;   Secondary Progressive Multiple SclerosisInterventions:   Biological: ATA188;   Drug: PlaceboSponsor:   Atara BiotherapeuticsActive, not recruiting

• A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy
  April 20, 2022
  Conditions:   Spinal Muscular Atrophy;   Neuromuscular Diseases;   SMAInterventions:   Drug: taldefgrobep alfa;   Drug: PlaceboSponsor:   Biohaven Pharmaceuticals, Inc.Recruiting
• Long-Term Follow-Up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA)
  February 10, 2022
  Condition:   Spinal Muscular AtrophyIntervention:   Drug: RisdiplamSponsor:   Genentech, Inc.Recruiting
• Sporadic Inclusion Body Myositis Natural History Study
  September 16, 2021
  Conditions:   Sporadic Inclusion Body Myositis;   Inclusion Body MyositisIntervention:   Sponsors:   University of California, Irvine;   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Recruiting
• Promoting Healing Of Nerves Through Electrical Stimulation
  December 10, 2020
  Conditions:   Cubital Tunnel Syndrome;   Nerve Compression;   Nerve Injury;   Ulnar NeuropathiesIntervention:   Device: Checkpoint BEST SystemSponsors:   Checkpoint Surgical Inc.;   Congressionally Directed Medical Research ProgramsRecruiting
• A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From SRP-9001 (Delandistrogene Moxeparvovec) in Participants With Duchenne Muscular Dystrophy (DMD)
  November 12, 2020
  Condition:   Muscular Dystrophy, DuchenneIntervention:   Genetic: SRP-9001Sponsors:   Sarepta Therapeutics, Inc.;   Hoffmann-La RocheEnrolling by invitation
• Tariquidar-ondansetron Combination in Neuropathic Pain
  October 26, 2020
  Condition:   Neuropathic PainInterventions:   Drug: Ondansetron 16 mg with Tariquidar;   Drug: Ondansetron 16 mg with PlaceboSponsor:   Washington University School of MedicineRecruiting
• Mechanomyography for Predictor of Prognosis in CuTS and PND Patients
  March 26, 2020
  Conditions:   Cubital Tunnel Syndrome;   Peroneal Nerve EntrapmentIntervention:   Device: Mechanomyography (MMG)Sponsors:   Washington University School of Medicine;   Mayo ClinicActive, not recruiting
• Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
  January 23, 2019
  Condition:   DermatomyositisInterventions:   Drug: Lenabasum 20 mg;   Drug: Lenabasum 5 mg;   Drug: PlaceboSponsor:   Corbus Pharmaceuticals Inc.Completed
• SOD1 Kinetics Measurements in ALS Patients
  February 28, 2018
  Conditions:   Amyotrophic Lateral Sclerosis, Familial;   Amyotrophic Lateral Sclerosis, SporadicIntervention:   Sponsors:   Washington University School of Medicine;   Massachusetts General HospitalSuspended
• PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
  October 22, 2015
  Conditions:   Sarcoma;   Malignant Peripheral Nerve Sheath TumorsInterventions:   Drug: PLX3397;   Drug: SirolimusSponsors:   Gulam Manji;   Daiichi Sankyo, Inc.Recruiting

• A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy
  April 20, 2022
  Conditions:   Spinal Muscular Atrophy;   Neuromuscular Diseases;   SMAInterventions:   Drug: taldefgrobep alfa;   Drug: PlaceboSponsor:   Biohaven Pharmaceuticals, Inc.Recruiting
• Long-Term Follow-Up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA)
  February 10, 2022
  Condition:   Spinal Muscular AtrophyIntervention:   Drug: RisdiplamSponsor:   Genentech, Inc.Recruiting
• A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From SRP-9001 (Delandistrogene Moxeparvovec) in Participants With Duchenne Muscular Dystrophy (DMD)
  November 12, 2020
  Condition:   Muscular Dystrophy, DuchenneIntervention:   Genetic: SRP-9001Sponsors:   Sarepta Therapeutics, Inc.;   Hoffmann-La RocheEnrolling by invitation
• AAV2/8-LSPhGAA (ACTUS-101) in Late-Onset Pompe Disease
  May 23, 2018
  Condition:   Pompe DiseaseIntervention:   Biological: ACTUS-101Sponsor:   Asklepios Biopharmaceutical, Inc.Recruiting

• A Study of Danavorexton in People With Obstructive Sleep Apnea After General Anesthesia for Abdominal Surgery
  April 14, 2023
  Condition:   Sleep ApneaInterventions:   Drug: Danavorexton;   Drug: PlaceboSponsor:   TakedaRecruiting
• Light Therapy for PD – Dose Selection
  March 2, 2020
  Conditions:   Parkinson Disease;   Sleep Disorder;   FatigueIntervention:   Device: SunRay Light BoxesSponsor:   Massachusetts General HospitalActive, not recruiting
• Hydromorphone vs Fentanyl in Children Undergoing Tonsillectomy Surgery
  January 18, 2020
  Conditions:   Obstructive Sleep Apnea;   TonsillitisInterventions:   Drug: Hydromorphone;   Drug: FentanylSponsor:   Washington University School of MedicineCompleted
• Closed Loop Acoustic Stimulation During Sedation With Dexmedetomidine
  December 20, 2019
  Conditions:   Sleep;   Sedation ComplicationInterventions:   Radiation: MRI;   Diagnostic Test: Quantitative Sensory Testing (QST);   Diagnostic Test: Home sleep study;   Other: Acoustic stimulation (65db) up-slope of EEG with QST;   Other: Acoustic stimulation (65db) down-slope of EEG with QST;   Other: 0 db with QST;   Drug: Dexmedetomidine;   Other: Breathe-Squeeze TaskSponsor:   Washington University School of MedicineActive, not recruiting
• Sleep for Stroke Management and Recovery Trial
  January 23, 2019
  Conditions:   Ischemic Stroke;   Sleep Apnea;   Sleep Apnea, Obstructive;   TIA;   Stroke;   CPAP;   Telemedicine;   Home Sleep Apnea Test;   Randomized Clinical Trial;   Multicenter TrialIntervention:   Device: CPAPSponsors:   University of Michigan;   National Institute of Neurological Disorders and Stroke (NINDS);   FusionHealth LLC;   Medical University of South Carolina;   University of CincinnatiRecruiting
• The Impact of Low Flow Nocturnal Oxygen Therapy on Hospital Admissions and Mortality in Patients With Heart Failure and Central Sleep Apnea
  November 19, 2018
  Conditions:   Heart Failure;   Central Sleep ApneaInterventions:   Drug: Oxygen;   Other: Room AirSponsors:   Brigham and Women's Hospital;   Ohio State UniversityTerminated
• Precision Event Monitoring for Patients With Heart Failure Using HeartLogic
  July 6, 2018
  Conditions:   Heart Failure;   Defibrillators, Implantable;   Monitoring, Physiologic;   Cardiac Resynchronization Therapy;   Cardiovascular Disease;   Heart DiseaseIntervention:   Device: HeartLogic SensorsSponsor:   Boston Scientific CorporationCompleted
• Postoperative Delirium: EEG Markers of Sleep and Wakefulness
  September 25, 2017
  Condition:   Postoperative DeliriumIntervention:   Sponsor:   Washington University School of MedicineActive, not recruiting
• MCI: CPAP Treatment of OSA (Memories2)
  April 13, 2017
  Conditions:   Mild Cognitive Impairment;   Sleep Apnea, ObstructiveIntervention:   Device: CPAPSponsors:   University of Pennsylvania;   National Institute on Aging (NIA)Active, not recruiting

• CANF-Comb-II PET-MR in Atherosclerosis Multisite
  May 1, 2023
  Conditions:   Carotid Atherosclerosis;   Asymptomatic Carotid Artery Stenosis;   Carotid Artery AtheromaIntervention:   Drug: 64Cu-25%-CANF-CombSponsors:   Washington University School of Medicine;   Cedars-Sinai Medical Center;   University of California, Santa Barbara;   National Heart, Lung, and Blood Institute (NHLBI)Recruiting
• A Study to Learn More About Asundexian (Also Called BAY2433334) for Prevention of Ischemic Stroke in Male and Female Participants Aged 18 Years and Older Who Already Had Such a Stroke Due to a Blood Clot That Formed Outside the Heart and Travelled to the Brain, or Temporary Stroke-like Symptoms
  January 17, 2023
  Conditions:   Prevention of Ischemic Stroke;   Acute Non-cardioembolic Ischemic Stroke;   High-risk Transient Ischemic AttackInterventions:   Drug: Asundexian (BAY2433334);   Drug: PlaceboSponsor:   BayerRecruiting
• REpeated ASSEssment of SurvivorS in Intracerebral Hemorrhage Study
  November 10, 2022
  Conditions:   Intra Cerebral Hemorrhage;   ICH – Intracerebral Hemorrhage;   ICH;   Hemorrhage;   Stroke;   Clot (Blood); Brain;   Clot Blood;   Cognitive Decline;   Cognitive Impairment;   Survivorship;   Memory Impairment;   Motor ActivityIntervention:   Sponsors:   Johns Hopkins University;   National Institute of Neurological Disorders and Stroke (NINDS)Enrolling by invitation
• Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct
  May 25, 2022
  Condition:   Acute Ischemic StrokeInterventions:   Device: transcutaneous auricular vagal nerve stimulation;   Device: Sham transcutaneous vagal nerve stimulationSponsor:   Washington University School of MedicineRecruiting
• Study of Crizanlizumab for Prevention of Silent Cerebral Infarcts in SCA
  April 19, 2022
  Condition:   Sickle Cell DiseaseIntervention:   Other: CrizanlizumabSponsors:   Andria Ford;   Novartis PharmaceuticalsRecruiting
• Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
  September 17, 2021
  Conditions:   Intracranial Arteriosclerosis;   StrokeInterventions:   Drug: Ticagrelor + Aspirin;   Drug: Rivaroxaban + Aspirin;   Drug: Clopidogrel + Aspirin;   Other: Risk Factor ManagementSponsors:   University of Florida;   National Institute of Neurological Disorders and Stroke (NINDS);   University of Cincinnati;   Medical University of South Carolina;   Janssen Scientific Affairs, LLC;   AstraZenecaRecruiting
• Stroke Thrombectomy and Aneurysm Registry
  August 6, 2021
  Conditions:   Stroke;   Thromboses, Intracranial;   Aneurysm, BrainIntervention:   Procedure: Stroke/Thrombectomy/Aneurysm-specific surgical proceduresSponsor:   Medical University of South CarolinaRecruiting
• The MIRROR Registry: Minimally Invasive IntRaceRebral HemORrhage Evacuation
  July 31, 2020
  Condition:   Supratentorial HemorrhageIntervention:   Device: Aurora Surgiscope SystemSponsors:   Integra LifeSciences Corporation;   Icahn School of Medicine at Mount Sinai;   Oculus Imaging LLCRecruiting
• Embolization of the Middle Meningeal Artery With ONYX™ Liquid Embolic System for Subacute and Chronic Subdural Hematoma
  May 27, 2020
  Condition:   Subdural HematomaInterventions:   Procedure: Surgical Management;   Device: Surgical Management + Treatment;   Other: No Treatment;   Device: TreatmentSponsor:   Medtronic Neurovascular Clinical AffairsRecruiting
• Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
  April 8, 2019
  Conditions:   Intracerebral Hemorrhage;   Atrial FibrillationInterventions:   Drug: Apixaban;   Drug: AspirinSponsors:   Yale University;   National Institute of Neurological Disorders and Stroke (NINDS)Recruiting
• Sleep for Stroke Management and Recovery Trial
  January 23, 2019
  Conditions:   Ischemic Stroke;   Sleep Apnea;   Sleep Apnea, Obstructive;   TIA;   Stroke;   CPAP;   Telemedicine;   Home Sleep Apnea Test;   Randomized Clinical Trial;   Multicenter TrialIntervention:   Device: CPAPSponsors:   University of Michigan;   National Institute of Neurological Disorders and Stroke (NINDS);   FusionHealth LLC;   Medical University of South Carolina;   University of CincinnatiRecruiting
• Multi-arm Optimization of Stroke Thrombolysis
  November 8, 2018
  Condition:   Acute Ischemic StrokeInterventions:   Drug: Argatroban;   Drug: Eptifibatide;   Drug: PlaceboSponsors:   Washington University School of Medicine;   National Institute of Neurological Disorders and Stroke (NINDS)Recruiting
• CERENOVUS Neurothrombectomy Devices Registry
  September 26, 2018
  Condition:   Cerebral StrokeInterventions:   Device: EmboTrap® Revascularization Device;   Device: CERENOVUS Large Bore Catheter/ EMBOVAC Aspiration CatheterSponsor:   Cerenovus, Part of DePuy Synthes Products, Inc.Recruiting
• Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial
  April 12, 2018
  Condition:   Intracerebral HemorrhageInterventions:   Biological: Recombinant Activated Factor VII (rFVIIa);   Biological: PlaceboSponsors:   Joseph Broderick, MD;   Novo Nordisk A/S;   National Institute of Neurological Disorders and Stroke (NINDS)Recruiting
• AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke
  June 20, 2017
  Condition:   StrokeInterventions:   Drug: Apixaban;   Drug: AspirinSponsors:   Columbia University;   National Institute of Neurological Disorders and Stroke (NINDS);   University of Cincinnati;   Medical University of South Carolina;   Bristol-Myers Squibb;   Pfizer;   Roche Pharma AG;   Weill Medical College of Cornell University;   University of WashingtonActive, not recruiting
• PET Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis
  April 16, 2015
  Condition:   Carotid AtherosclerosisIntervention:   Device: Cu[64]-25%-CANF-Comb PET-MRSponsor:   Washington University School of MedicineCompleted
• Systematic Assessment and Targeted Improvement of Services Following Yearlong Surgical Outcomes Surveys
  January 9, 2014
  Conditions:   Heart Attack;   Cardiac Arrest;   Congestive Heart Failure;   Atrial Fibrillation;   Angina;   Deep Vein Thrombosis;   Pulmonary Embolism;   Respiratory Arrest;   Respiratory Failure;   Pneumonia;   Gastrointestinal Bleed;   Stomach Ulcer;   Delirium;   Stroke;   Nerve Injury;   Surgical Wound InfectionIntervention:   Sponsor:   Washington University School of MedicineCompleted